GENITOURINARY CANCERS

With a little help from a negotiation expert, prostate cancer specialists persuaded significantly more men with low-risk prostate cancer to enroll in active surveillance, results of an observational study showed.

A high rate of PSA testing in the control arm of the Prostate, Lung, Colorectal, and Ovary screening trial made meaningful comparisons with the intervention group impossible, according to a new analysis of data from the landmark trial.

A. Oliver Sartor, MD, Medical Director of Tulane Cancer Center, explains why primary care physicians and oncologists/urologists have differences of opinion when it comes to prostate-specific antigen (PSA) testing.

Abiraterone acetate in combination with low-dose prednisone showed a low overall incidence of corticosteroid-associated adverse events that were not significantly different compared with prednisone alone for patients with metastatic castration-resistant prostate cancer.

Neal Shore, MD, medical director of Carolina Urologic Research Center, discusses corticosteroid-associated adverse events with low-dose prednisone given with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC).

For decades, the standard of care for men with advanced prostate cancer has been the depletion or inhibition of androgens. While androgen-deprivation therapy (ADT) often results in temporary tumor regression or symptom relief in some patients, disease progression ultimately occurs over time.

Several recent studies have investigated the safety and efficacy of next-generation antiandrogen therapies and chemotherapy in the geriatric population.

As the treatment landscape for patients with metastatic castration-resistant prostate cancer (CRPC) continues to evolve, optimal strategies are becoming more apparent on how to best sequence the multitude of novel therapies that have been approved in the past decade.

Since 2010, several novel therapies have been approved for use in metastatic castration-resistant prostate cancer (mCRPC). Although they have expanded the therapeutic repertoire for clinicians, they also bring a new set of challenges for the optimal clinical management of patients with mCRPC.

Within the past 5 years, several agents have become available for the treatment of metastatic castration-resistant prostate cancer (mCRPC) based on survival benefits observed in randomized clinical trials

Androgen deprivation therapy (ADT) has been the standard of care for patients with advanced prostate cancer; however, a majority of patients on hormonal therapy become unresponsive to treatment after an initial response.

Bone metastases in metastatic castration-resistant prostate cancer (mCRPC) can invade a range of sites in the skeleton where they precipitate a spectrum of pathological processes that increase morbidity, negatively affect quality of life, and decrease survival.

Novel combination approaches are currently under exploration that hope to capitalize on the varying mechanisms of action for each newly approved agent for men with metastatic castration-resistant prostate cancer (mCRPC).

The explosion of new drugs for the treatment of castration-resistant prostate cancer (CRPC) is a welcome advance, but raises questions about how best to sequence these drugs with standard docetaxel chemotherapy.

Therapeutic options have grown considerably in recent years for men with metastatic, castration-resistant prostate cancer (mCRPC), with studies currently looking to combine these new options.

Circulating tumor cells (CTCs) have been recognized as a potential source of prostate cancer seeding to distant metastatic sites (typically bone) for over a century, and with ongoing improvements in isolation and characterization methodology, CTCs are now being more rigorously investigated as potential predictive biomarkers in men with mCRPC.

Despite what many believe, not all radiopharmaceuticals are just for pain palliation, according to Phillip J. Koo, MD.

In an interview with Targeted Oncology, Stacy Loeb, MD discusses how these PSA tests work, what their benefits are, and what urological specialists need to know in order to best utilize them.

Cooperberg says a growing body of evidence dictates that surgery in prostate cancer may be a more effective local therapy than radiation alone.

The amount of vitamin D in a man's blood could be an effective biomarker to identify an aggressive form of prostate cancer, doubly so for men who are considering active surveillance.

An abiraterone acetate (Zytiga) plus prednisone combination showcased an 11.8-month improvement in overall survival (OS) when compared with prednisone and placebo in less advanced, chemotherapy-naive metastatic castration-resistant prostate cancer.

Men whose prostate cancer is treated with radiotherapy had a higher risk of developing secondary malignancies in the bladder, colon, and rectum, as compared with men who were not exposed to radiotherapy.

The PD-L1 inhibitor atezolizumab (MPDL3280A) showed promising antitumor activity in patients with inoperable locally advanced or metastatic urothelial carcinoma whose disease had progressed after previous platinum-based chemotherapy.

The FDA has accepted a supplemental new drug application for a capsulated form of enzalutamide for review in patients with metastatic castration-resistant prostate cancer. This application includes findings from the head-to-head studies, TERRAIN and STRIVE.

With no significant difference between intermittent and continuous androgen-deprivation therapy, patients with prostate cancer may experience an improvement in their quality of life with the former.

While still in its early stages, integrative genomic testing could be the future for personalizing therapy for patients with castration-resistant prostate cancer (CRPC), according to Tomasz M. Beer, MD, FACP.

While the US Preventive Services Task Force (USPSTF) has issued recommendations against routine PSA-based screening for prostate cancer, E. David Crawford, MD, feels as though this is a step in the wrong direction.

Cooperberg says the likelihood of a patient for staying on active surveillance for 10 or 15 years is around 50%, though men who stay on active surveillance for between 6 months and 5 years generally see progression in their disease.

Oliver Sartor, MD, medical director, Tulane Cancer Center, discusses how radium-223 dichloride became deemed safe in patients with bone-metastatic castration-resistant prostate cancer (CRPC). The treatment was tested in an open-label phase I/II trial where patients were given 6 additional doses of radium-223 on top of their original 6-dose regimen.

Single-dose fosaprepitant dimeglumine (Emend for injection) in combination with antiemetic agents has been approved by the FDA for the preventing